Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2023-08-18 Director's Dealing
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2023-08-18 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 10, 2023, reporting the results of operations for the quarter ended June 30, 2023. It specifically states that it includes a press release with financial results and is furnished under Item 2.02 (Results of Operations and Financial Condition). The document is relatively short (3637 characters) and primarily serves to announce the earnings release rather than providing detailed financial statements or comprehensive analysis. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER).
2023-08-10 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 2, 2023, reporting the entry into a material definitive agreement related to an underwritten public offering of common stock by Tarsus Pharmaceuticals, Inc. The text details the underwriting agreement terms, the number of shares, pricing, and expected proceeds. It also references press releases announcing the offering and pricing. There are no financial statements or detailed financial performance data included, only information about the financing transaction. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length is 7,907 characters, sufficient to contain substantive information about the financing event rather than just an announcement or a brief notice. Therefore, the appropriate classification is CAP with high confidence.
2023-08-02 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to a public offering of common stock by Tarsus Pharmaceuticals, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and other related disclosures. The document is filed pursuant to Rule 424(b)(5), which is a SEC rule for prospectus supplements related to securities offerings. This type of document is a capital/financing update as it provides information about the company's fundraising activity through the sale of shares. It is not an annual or quarterly report, audit report, earnings release, or any other type of report. It is also not a regulatory filing unrelated to financing, nor a proxy or governance document. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2023-08-02 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of $100 million of common stock by Tarsus Pharmaceuticals, Inc., including underwriting details, risk factors, use of proceeds, and other offering-related information. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other report type. It is clearly related to a financing activity and capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief notice, so it is not an RPA or RNS. Confidence is high given the clear identification of the document as a prospectus supplement for a stock offering.
2023-07-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.